Key terms
About RMD
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RMD news
Yesterday
11:20am ET
RBC says small surprise in Lilly’s trial could be viewed as positive for ResMed
Yesterday
10:39am ET
Inspire rises, ResMed slips as Street digests data from Lilly sleep apnea trials
Yesterday
9:15am ET
KeyBanc views Lilly’s SURMOUNT-OSA results as ‘a bit of a relief’ for Inspire
Yesterday
8:55am ET
ResMed, Inspire Medical slip after Lilly sleep apnea trials meet goal
Yesterday
5:10am ET
Resmed Stock Poised for Growth: Buy Rating Affirmed Amid Revenue Upswing and Margin Expansion
Apr 12
1:50am ET
Analysts Are Bullish on Top Healthcare Stocks: InMode (INMD), Resmed (RMD)
Apr 01
9:20am ET
ResMed price target raised to $224 from $215 at Needham
Apr 01
5:35am ET
Analyst Upgrades Resmed Price Target to $224, Maintains Buy Rating Amidst Market Opportunities and OSA Trial Developments
Mar 28
12:20am ET
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Merck & Company (MRK)
Mar 22
5:20am ET
Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS)
Mar 22
5:10am ET
Analysts Are Bullish on These Healthcare Stocks: Addus Homecare (ADUS), Resmed (RMD)
Mar 20
2:38pm ET
LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint
Mar 07
9:55am ET
Early notable gainers among liquid option names on March 7th
Mar 06
9:08am ET
ResMed announces launch of AirFit F40
Feb 06
9:55am ET
Tesla downgraded, UPS upgraded: Wall Street’s top analyst calls
Feb 06
4:48am ET
ResMed resumed with an Overweight at KeyBanc
Jan 30
11:15pm ET
Oppenheimer Keeps Their Buy Rating on Resmed (RMD)
Jan 30
8:51pm ET
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Demant (OtherWILLF)
Jan 30
6:38am ET
ResMed price target raised to $215 from $195 at Mizuho
Jan 29
7:36am ET
Resmed Stock Buy Rating Affirmed Amidst Market Opportunity and Strong Financials
Jan 26
7:00am ET
ResMed price target raised to $195 from $180 at Mizuho
Jan 25
6:48pm ET
ResMed CEO: Our resupply rate is higher due to GLP-1 drugs
Jan 25
9:55am ET
Early notable gainers among liquid option names on January 25th
Jan 25
9:47am ET
ResMed rises 10.4%
Jan 25
9:27am ET
ResMed price target raised to $182 from $181 at RBC Capital
Jan 25
8:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 25
7:35am ET
ResMed price target raised to $215 from $180 at Needham
Jan 25
7:32am ET
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Resmed (RMD) and Clinigence Holdings (NUTX)
Jan 25
6:25am ET
Resmed Receives Strong Buy Rating on Robust Sales, Margin Expansion, and Promising Treatment Synergies
Jan 25
6:25am ET
ResMed price target raised to $198 from $195 at JPMorgan
Jan 25
6:05am ET
Buy Rating Affirmed for Resmed on Strong Financials and Positive Strategic Outlook
No recent press releases are available for RMD
RMD Financials
Key terms
Ad Feedback
RMD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RMD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
